Published in PLoS One on May 31, 2013
Vaccine-elicited human T cells recognizing conserved protein regions inhibit HIV-1. Mol Ther (2013) 1.61
T cell responses to viral infections - opportunities for Peptide vaccination. Front Immunol (2014) 0.95
Differential impact of magnitude, polyfunctional capacity, and specificity of HIV-specific CD8+ T cell responses on HIV set point. J Virol (2013) 0.92
A human immune data-informed vaccine concept elicits strong and broad T-cell specificities associated with HIV-1 control in mice and macaques. J Transl Med (2015) 0.92
Early Kinetics of the HLA Class I-Associated Peptidome of MVA.HIVconsv-Infected Cells. J Virol (2015) 0.83
Characterization of the Protective HIV-1 CTL Epitopes and the Corresponding HLA Class I Alleles: A Step towards Designing CTL Based HIV-1 Vaccine. Adv Virol (2014) 0.83
Short conserved sequences of HIV-1 are highly immunogenic and shift immunodominance. J Virol (2014) 0.81
CD8(+) T-cell Cytotoxic Capacity Associated with Human Immunodeficiency Virus-1 Control Can Be Mediated through Various Epitopes and Human Leukocyte Antigen Types. EBioMedicine (2014) 0.80
The HIV-1 antisense protein (ASP) induces CD8 T cell responses during chronic infection. Retrovirology (2015) 0.79
Vaccination With Heterologous HIV-1 Envelope Sequences and Heterologous Adenovirus Vectors Increases T-Cell Responses to Conserved Regions: HVTN 083. J Infect Dis (2015) 0.79
A proposal to use iterative, small clinical trials to optimize therapeutic HIV vaccine immunogens to launch therapeutic HIV vaccine development. AIDS Res Hum Retroviruses (2015) 0.78
Composite Sequence-Structure Stability Models as Screening Tools for Identifying Vulnerable Targets for HIV Drug and Vaccine Development. Viruses (2015) 0.77
In silico design of a DNA-based HIV-1 multi-epitope vaccine for Chinese populations. Hum Vaccin Immunother (2015) 0.76
Detection of Broadly Neutralizing Activity within the First Months of HIV-1 Infection. J Virol (2016) 0.75
Human Immunodeficiency Virus (HIV). Transfus Med Hemother (2016) 0.75
The value of HIV protective epitope research for informed vaccine design against diverse viral pathogens. Expert Rev Vaccines (2014) 0.75
HIV-1 Conserved Mosaics Delivered by Regimens with Integration-Deficient DC-Targeting Lentiviral Vector Induce Robust T Cells. Mol Ther (2017) 0.75
Human Leukocyte Antigen (HLA) and Immune Regulation: How Do Classical and Non-Classical HLA Alleles Modulate Immune Response to Human Immunodeficiency Virus and Hepatitis C Virus Infections? Front Immunol (2017) 0.75
Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med (2009) 28.62
HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells. Blood (2006) 17.38
Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J Virol (1994) 15.93
A whole-genome association study of major determinants for host control of HIV-1. Science (2007) 15.19
Dramatic rise in plasma viremia after CD8(+) T cell depletion in simian immunodeficiency virus-infected macaques. J Exp Med (1999) 14.30
Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med (2012) 12.98
Late escape from an immunodominant cytotoxic T-lymphocyte response associated with progression to AIDS. Nat Med (1997) 12.26
Antiviral pressure exerted by HIV-1-specific cytotoxic T lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus. Nat Med (1997) 12.08
Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA. Science (1998) 12.05
CD8+ T-cell responses to different HIV proteins have discordant associations with viral load. Nat Med (2006) 10.34
HIV evolution: CTL escape mutation and reversion after transmission. Nat Med (2004) 10.21
The major genetic determinants of HIV-1 control affect HLA class I peptide presentation. Science (2010) 9.61
Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine. Nature (2011) 9.30
HLA and HIV-1: heterozygote advantage and B*35-Cw*04 disadvantage. Science (1999) 8.11
Positive selection of HIV-1 cytotoxic T lymphocyte escape variants during primary infection. Proc Natl Acad Sci U S A (1997) 8.05
The influence of HLA genotype on AIDS. Annu Rev Med (2001) 7.77
Analysis of total human immunodeficiency virus (HIV)-specific CD4(+) and CD8(+) T-cell responses: relationship to viral load in untreated HIV infection. J Virol (2001) 7.37
Superior control of HIV-1 replication by CD8+ T cells is reflected by their avidity, polyfunctionality, and clonal turnover. J Exp Med (2007) 5.58
Magnitude of functional CD8+ T-cell responses to the gag protein of human immunodeficiency virus type 1 correlates inversely with viral load in plasma. J Virol (2002) 4.65
Cellular immune responses to HIV. Nature (2001) 4.61
The role of antibodies in HIV vaccines. Annu Rev Immunol (2010) 4.50
Cellular immune responses and viral diversity in individuals treated during acute and early HIV-1 infection. J Exp Med (2001) 4.42
Adaptation of HIV-1 to human leukocyte antigen class I. Nature (2009) 4.24
Consistent cytotoxic-T-lymphocyte targeting of immunodominant regions in human immunodeficiency virus across multiple ethnicities. J Virol (2004) 4.12
Escape and compensation from early HLA-B57-mediated cytotoxic T-lymphocyte pressure on human immunodeficiency virus type 1 Gag alter capsid interactions with cyclophilin A. J Virol (2007) 3.93
Maintenance of large numbers of virus-specific CD8+ T cells in HIV-infected progressors and long-term nonprogressors. J Immunol (2000) 3.83
Common genetic variation and the control of HIV-1 in humans. PLoS Genet (2009) 3.68
Comparison of site-specific rate-inference methods for protein sequences: empirical Bayesian methods are superior. Mol Biol Evol (2004) 3.62
Gag-specific CD8+ T lymphocytes recognize infected cells before AIDS-virus integration and viral protein expression. J Immunol (2007) 3.59
ConSeq: the identification of functionally and structurally important residues in protein sequences. Bioinformatics (2004) 3.50
Mosaic HIV-1 vaccines expand the breadth and depth of cellular immune responses in rhesus monkeys. Nat Med (2010) 3.44
Hierarchical targeting of subtype C human immunodeficiency virus type 1 proteins by CD8+ T cells: correlation with viral load. J Virol (2004) 3.28
Induction of immunity to human immunodeficiency virus type-1 by vaccination. Immunity (2010) 3.25
Peptide selection for human immunodeficiency virus type 1 CTL-based vaccine evaluation. Vaccine (2006) 2.89
Protection by live, attenuated simian immunodeficiency virus against heterologous challenge. J Virol (1999) 2.65
Comprehensive analysis of human immunodeficiency virus type 1 (HIV-1)-specific gamma interferon-secreting CD8+ T cells in primary HIV-1 infection. J Virol (2003) 2.64
Design and pre-clinical evaluation of a universal HIV-1 vaccine. PLoS One (2007) 2.61
Macaques vaccinated with live-attenuated SIV control replication of heterologous virus. J Exp Med (2008) 2.59
Target structures of the CD8(+)-T-cell response to human cytomegalovirus: the 72-kilodalton major immediate-early protein revisited. J Virol (1999) 2.55
Enhanced detection of human immunodeficiency virus type 1-specific T-cell responses to highly variable regions by using peptides based on autologous virus sequences. J Virol (2003) 2.53
Mosaic vaccines elicit CD8+ T lymphocyte responses that confer enhanced immune coverage of diverse HIV strains in monkeys. Nat Med (2010) 2.53
Putative immunodominant human immunodeficiency virus-specific CD8(+) T-cell responses cannot be predicted by major histocompatibility complex class I haplotype. J Virol (2000) 2.51
Human immunodeficiency virus type 1-specific CD8+ T-cell responses during primary infection are major determinants of the viral set point and loss of CD4+ T cells. J Virol (2009) 2.51
Selection on the human immunodeficiency virus type 1 proteome following primary infection. J Virol (2006) 2.48
HIV-1 group M conserved elements vaccine. PLoS Pathog (2007) 2.28
Preservation of T cell proliferation restricted by protective HLA alleles is critical for immune control of HIV-1 infection. J Immunol (2006) 2.17
Persistent recognition of autologous virus by high-avidity CD8 T cells in chronic, progressive human immunodeficiency virus type 1 infection. J Virol (2004) 2.07
Lymph node T cell responses predict the efficacy of live attenuated SIV vaccines. Nat Med (2012) 1.86
Hitting HIV where it hurts: an alternative approach to HIV vaccine design. Trends Immunol (2006) 1.74
Definition of the viral targets of protective HIV-1-specific T cell responses. J Transl Med (2011) 1.73
Protective HIV-specific CD8+ T cells evade Treg cell suppression. Nat Med (2011) 1.66
Selective depletion of high-avidity human immunodeficiency virus type 1 (HIV-1)-specific CD8+ T cells after early HIV-1 infection. J Virol (2007) 1.61
Absolute copy number and relative change in determinations of human immunodeficiency virus type 1 RNA in plasma: effect of an external standard on kit comparisons. J Clin Microbiol (1998) 1.60
Enhanced anti-HIV functional activity associated with Gag-specific CD8 T-cell responses. J Virol (2010) 1.60
CTL responses of high functional avidity and broad variant cross-reactivity are associated with HIV control. PLoS One (2012) 1.48
High-functional-avidity cytotoxic T lymphocyte responses to HLA-B-restricted Gag-derived epitopes associated with relative HIV control. J Virol (2011) 1.44
Virus-specific CD8+ T-cell responses better define HIV disease progression than HLA genotype. J Virol (2010) 1.39
Enhanced detection of human immunodeficiency virus type 1 (HIV-1) Nef-specific T cells recognizing multiple variants in early HIV-1 infection. J Virol (2007) 1.32
Broadly cross-reactive HIV-specific cytotoxic T-lymphocytes in highly-exposed persistently seronegative donors. Immunol Lett (1999) 1.32
Efficacious early antiviral activity of HIV Gag- and Pol-specific HLA-B 2705-restricted CD8+ T cells. J Virol (2010) 1.26
CD8 T-cell responses in early HIV-1 infection are skewed towards high entropy peptides. AIDS (2005) 1.26
How important is the 'quality' of the cytotoxic T lymphocyte (CTL) response in protection against HIV infection? Immunol Lett (2001) 1.24
Characterization of CD8 T-cell responses in HIV-1-exposed seronegative commercial sex workers from Nairobi, Kenya. Immunol Cell Biol (2006) 1.17
Mapping the landscape of host-pathogen coevolution: HLA class I binding and its relationship with evolutionary conservation in human and viral proteins. J Virol (2010) 1.17
Mapping HIV-1 vaccine induced T-cell responses: bias towards less-conserved regions and potential impact on vaccine efficacy in the Step study. PLoS One (2011) 1.16
Evolutionary modeling of rate shifts reveals specificity determinants in HIV-1 subtypes. PLoS Comput Biol (2008) 1.05
Broad human immunodeficiency virus (HIV)-specific T cell responses to conserved HIV proteins in HIV-seronegative women highly exposed to a single HIV-infected partner. J Infect Dis (2003) 1.05
A new multiplex PCR strategy for the simultaneous determination of four genetic polymorphisms affecting HIV-1 disease progression. J Immunol Methods (2001) 1.00
Preclinical evaluation of HIV-1 therapeutic ex vivo dendritic cell vaccines expressing consensus Gag antigens and conserved Gag epitopes. Vaccine (2011) 0.96
Conserved HIV-1 epitopes continuously elicit subdominant cytotoxic T-lymphocyte responses. J Infect Dis (2009) 0.96
HLA-B molecules target more conserved regions of the HIV-1 proteome. AIDS (2010) 0.93
HIV vaccine development at the turn of the 21st century. Curr Opin HIV AIDS (2012) 0.90
Short communication: CD8(+) T cell polyfunctionality profiles in progressive and nonprogressive pediatric HIV type 1 infection. AIDS Res Hum Retroviruses (2011) 0.89
Induction of human immunodeficiency virus type 1 (HIV-1)-specific T-cell responses in HIV vaccine trial participants who subsequently acquire HIV-1 infection. J Virol (2006) 0.86
Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med (2009) 19.90
CD8+ T-cell responses to different HIV proteins have discordant associations with viral load. Nat Med (2006) 10.34
Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med (2002) 9.70
HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors. J Neurovirol (2010) 7.56
Factors associated with the development of cross-reactive neutralizing antibodies during human immunodeficiency virus type 1 infection. J Virol (2008) 7.14
Validation of the CNS Penetration-Effectiveness rank for quantifying antiretroviral penetration into the central nervous system. Arch Neurol (2008) 6.91
KCNQ1 gain-of-function mutation in familial atrial fibrillation. Science (2003) 6.60
Fitness cost of escape mutations in p24 Gag in association with control of human immunodeficiency virus type 1. J Virol (2006) 6.30
Tiered categorization of a diverse panel of HIV-1 Env pseudoviruses for assessment of neutralizing antibodies. J Virol (2009) 5.91
Profiling the specificity of neutralizing antibodies in a large panel of plasmas from patients chronically infected with human immunodeficiency virus type 1 subtypes B and C. J Virol (2008) 5.69
The translational landscape of mTOR signalling steers cancer initiation and metastasis. Nature (2012) 5.61
The TEAD/TEF family protein Scalloped mediates transcriptional output of the Hippo growth-regulatory pathway. Dev Cell (2008) 5.58
Towards an HIV cure: a global scientific strategy. Nat Rev Immunol (2012) 5.52
Genital HIV-1 RNA predicts risk of heterosexual HIV-1 transmission. Sci Transl Med (2011) 5.21
The prevalence and incidence of neurocognitive impairment in the HAART era. AIDS (2007) 5.18
Acute phase cytotoxic T lymphocyte escape is a hallmark of simian immunodeficiency virus infection. Nat Med (2002) 5.17
Persistence of HIV in gut-associated lymphoid tissue despite long-term antiretroviral therapy. J Infect Dis (2008) 4.86
mTORC1-mediated cell proliferation, but not cell growth, controlled by the 4E-BPs. Science (2010) 4.81
Attenuated cold sensitivity in TRPM8 null mice. Neuron (2007) 4.73
Founder effects in the assessment of HIV polymorphisms and HLA allele associations. Science (2007) 4.60
Mitogenic influence of human R-spondin1 on the intestinal epithelium. Science (2005) 4.58
Improved coreceptor usage prediction and genotypic monitoring of R5-to-X4 transition by motif analysis of human immunodeficiency virus type 1 env V3 loop sequences. J Virol (2003) 4.56
Standardization of cytokine flow cytometry assays. BMC Immunol (2005) 4.55
Insulin modulates gluconeogenesis by inhibition of the coactivator TORC2. Nature (2007) 4.54
Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy. N Engl J Med (2009) 4.54
Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1. Ann Intern Med (2011) 4.21
Mesenchymal stem cell-mediated functional tooth regeneration in swine. PLoS One (2006) 3.91
White Collar-1, a circadian blue light photoreceptor, binding to the frequency promoter. Science (2002) 3.85
Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env V2. Nature (2012) 3.83
Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK. Proc Natl Acad Sci U S A (2006) 3.83
Association between adverse clinical outcome in human disease caused by novel influenza A H7N9 virus and sustained viral shedding and emergence of antiviral resistance. Lancet (2013) 3.83
Late presentation for human immunodeficiency virus care in the United States and Canada. Clin Infect Dis (2010) 3.72
HIV-infected individuals receiving effective antiviral therapy for extended periods of time continually replenish their viral reservoir. J Clin Invest (2005) 3.62
Decay of the HIV reservoir in patients receiving antiretroviral therapy for extended periods: implications for eradication of virus. J Infect Dis (2007) 3.50
Targeting Bcr-Abl by combining allosteric with ATP-binding-site inhibitors. Nature (2010) 3.39
Defining blood processing parameters for optimal detection of cryopreserved antigen-specific responses for HIV vaccine trials. J Immunol Methods (2007) 3.29
Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor. Nat Med (2010) 3.26
Rebound of plasma viremia following cessation of antiretroviral therapy despite profoundly low levels of HIV reservoir: implications for eradication. AIDS (2010) 3.26
R-Spondin1 regulates Wnt signaling by inhibiting internalization of LRP6. Proc Natl Acad Sci U S A (2007) 3.24
Control of human immunodeficiency virus replication by cytotoxic T lymphocytes targeting subdominant epitopes. Nat Immunol (2005) 3.23
The p110 delta structure: mechanisms for selectivity and potency of new PI(3)K inhibitors. Nat Chem Biol (2010) 3.15
White collar-1, a DNA binding transcription factor and a light sensor. Science (2002) 2.97
Allosteric inhibitors of Bcr-abl-dependent cell proliferation. Nat Chem Biol (2006) 2.96
Characterization of the apical papilla and its residing stem cells from human immature permanent teeth: a pilot study. J Endod (2008) 2.95
Mucopurulent cervicitis and Mycoplasma genitalium. J Infect Dis (2003) 2.88
Practical reconstruction method for bioluminescence tomography. Opt Express (2005) 2.83
Evidence that low-level viremias during effective highly active antiretroviral therapy result from two processes: expression of archival virus and replication of virus. J Virol (2005) 2.82
Pervasive genomic recombination of HIV-1 in vivo. Genetics (2004) 2.79
Central role of reverting mutations in HLA associations with human immunodeficiency virus set point. J Virol (2008) 2.72
Virus population homogenization following acute human immunodeficiency virus type 1 infection. J Virol (2002) 2.71
Genetic impact of vaccination on breakthrough HIV-1 sequences from the STEP trial. Nat Med (2011) 2.71
Identification of a KCNE2 gain-of-function mutation in patients with familial atrial fibrillation. Am J Hum Genet (2004) 2.66
Cryptochrome mediates circadian regulation of cAMP signaling and hepatic gluconeogenesis. Nat Med (2010) 2.65
A-803467, a potent and selective Nav1.8 sodium channel blocker, attenuates neuropathic and inflammatory pain in the rat. Proc Natl Acad Sci U S A (2007) 2.60
A Kir2.1 gain-of-function mutation underlies familial atrial fibrillation. Biochem Biophys Res Commun (2005) 2.55
Enhanced detection of human immunodeficiency virus type 1-specific T-cell responses to highly variable regions by using peptides based on autologous virus sequences. J Virol (2003) 2.53
Dominance of CD8 responses specific for epitopes bound by a single major histocompatibility complex class I molecule during the acute phase of viral infection. J Virol (2002) 2.50
Selection on the human immunodeficiency virus type 1 proteome following primary infection. J Virol (2006) 2.48
Estimating the impact of plasma HIV-1 RNA reductions on heterosexual HIV-1 transmission risk. PLoS One (2010) 2.48
Cellular gene expression upon human immunodeficiency virus type 1 infection of CD4(+)-T-cell lines. J Virol (2003) 2.46
The cytolytic enzymes granyzme A, granzyme B, and perforin: expression patterns, cell distribution, and their relationship to cell maturity and bright CD57 expression. J Leukoc Biol (2008) 2.44
CCL2/CCR2 pathway mediates recruitment of myeloid suppressor cells to cancers. Cancer Lett (2007) 2.43
Pure spinal epidural cavernous hemangioma. Acta Neurochir (Wien) (2012) 2.38
Mesenchymal stem cells derived from human gingiva are capable of immunomodulatory functions and ameliorate inflammation-related tissue destruction in experimental colitis. J Immunol (2009) 2.37
Viral linkage in HIV-1 seroconverters and their partners in an HIV-1 prevention clinical trial. PLoS One (2011) 2.36
Variable fitness impact of HIV-1 escape mutations to cytotoxic T lymphocyte (CTL) response. PLoS Pathog (2009) 2.36
Imaging P-glycoprotein transport activity at the human blood-brain barrier with positron emission tomography. Clin Pharmacol Ther (2005) 2.35
Sex, race, and geographic region influence clinical outcomes following primary HIV-1 infection. J Infect Dis (2011) 2.34
Phylogenetic dependency networks: inferring patterns of CTL escape and codon covariation in HIV-1 Gag. PLoS Comput Biol (2008) 2.32
Multiple viral genetic analyses detect low-level human immunodeficiency virus type 1 replication during effective highly active antiretroviral therapy. J Virol (2003) 2.31
CD4 nadir is a predictor of HIV neurocognitive impairment in the era of combination antiretroviral therapy. AIDS (2011) 2.31
HIV-1 group M conserved elements vaccine. PLoS Pathog (2007) 2.28
A general strategy for creating "inactive-conformation" abl inhibitors. Chem Biol (2006) 2.27
Control of human immunodeficiency virus type 1 is associated with HLA-B*13 and targeting of multiple gag-specific CD8+ T-cell epitopes. J Virol (2007) 2.26
Changes in human immunodeficiency virus type 1 fitness and genetic diversity during disease progression. J Virol (2005) 2.25
Consensus and ancestral state HIV vaccines. Science (2003) 2.24
Diverse pathways generate microRNA-like RNAs and Dicer-independent small interfering RNAs in fungi. Mol Cell (2010) 2.23
Safety, pharmacokinetics, and antiviral activity of AMD3100, a selective CXCR4 receptor inhibitor, in HIV-1 infection. J Acquir Immune Defic Syndr (2004) 2.21
Dual HIV-1 infection associated with rapid disease progression. Lancet (2004) 2.17
Non-optimal codon usage affects expression, structure and function of clock protein FRQ. Nature (2013) 2.15
HLA class I-driven evolution of human immunodeficiency virus type 1 subtype c proteome: immune escape and viral load. J Virol (2008) 2.14
ViroBLAST: a stand-alone BLAST web server for flexible queries of multiple databases and user's datasets. Bioinformatics (2007) 2.13
Abacavir/lamivudine versus tenofovir DF/emtricitabine as part of combination regimens for initial treatment of HIV: final results. J Infect Dis (2011) 2.12
Conflicting selective forces affect T cell receptor contacts in an immunodominant human immunodeficiency virus epitope. Nat Immunol (2006) 2.11
Cooperative interactions between CBP and TORC2 confer selectivity to CREB target gene expression. EMBO J (2007) 2.07
Regulation of the Neurospora circadian clock by an RNA helicase. Genes Dev (2004) 2.07
Broad and Gag-biased HIV-1 epitope repertoires are associated with lower viral loads. PLoS One (2008) 2.06
qiRNA is a new type of small interfering RNA induced by DNA damage. Nature (2009) 2.06
A reliable phenotype predictor for human immunodeficiency virus type 1 subtype C based on envelope V3 sequences. J Virol (2006) 2.05